Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics Announces Podium Presentation of FX301 Preclinical Data at Virtual ANESTHESIOLOGY 2020 Meeting
Previously presented preclinical findings show FX301 provided greater sustained, post-operative analgesic effect with no significant impairment in motor function compared to liposomal bupivacaine and placebo   BURLINGTON, Mass. , Oct. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc.
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Oct. 02, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of
View HTML
Toggle Summary Flexion Therapeutics to Present at the H.C. Wainwright Virtual Healthcare Conference
BURLINGTON, Mass. , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the H.C. Wainwright Virtual Healthcare Conference . The virtual
View HTML
Toggle Summary Flexion Therapeutics Announces Treatment of First Patient in Second Cohort of FX201 Phase 1 Dose-Escalation Trial
Five patients treated in first cohort of Phase 1 clinical trial evaluating the safety and tolerability of FX201; Drug Monitoring Committee (DMC) supported the initiation of the next dosing cohort BURLINGTON, Mass. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc.
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Sept. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to three new employees consisting of 13,940 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective
View HTML
Toggle Summary Flexion Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference
BURLINGTON, Mass. , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2020 Virtual Healthcare Conference . The virtual
View HTML
Toggle Summary Flexion Therapeutics Announces Appointment of Liz Kwo, MD, to its Board of Directors
BURLINGTON, Mass. , Aug. 19, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Elizabeth (Liz) Kwo , MD, Staff Vice President, Clinical Data Analytics at Anthem, to its Board of Directors. "We are delighted to welcome Liz to our Board of Directors
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Aug. 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 25,315 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date
View HTML
Toggle Summary Flexion Therapeutics Reports Second-Quarter 2020 Financial Results and Recent Business Highlights
Company reported ZILRETTA®  ( triamcinolone acetonide extended-release injectable suspension) net sales of $15.5 million in second quarter 2020 Flexion resumed enrollment in Phase 1 dose-escalation trial for FX201; FX301 on track to enter clinic in 2021 BURLINGTON, Mass. , Aug.
View HTML
Toggle Summary Flexion Therapeutics to Report Second-Quarter 2020 Financial Results on August 5, 2020
BURLINGTON, Mass. , July 30, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2020 financial results and recent business highlights after the close of the U.S. financial markets on Wednesday, August 5, 2020 .
View HTML